• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of archdischArchives of Disease in ChildhoodVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Arch Dis Child. Nov 2003; 88(11): 969–973.
PMCID: PMC1719352

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

Abstract

Aims: To measure pimecrolimus blood concentrations and to evaluate tolerability and efficacy in children and infants treated topically for atopic dermatitis with pimecrolimus cream 1% for three weeks.

Methods: Three open label, non-controlled, multiple topical dose studies were conducted in children aged 8–14 years (study A, ten patients), and in infants aged 8–30 months (study B, eight patients) and 4–11 months (study C, eight patients). Pimecrolimus blood concentrations were determined on days 4 and 22 of treatment, and at end of study. Efficacy was assessed using the Eczema Area and Severity Index (EASI).

Results: Pimecrolimus blood concentrations were consistently low, typically (81%) below 1 ng/ml, with more than half of the measurements below the assay limit of quantitation (0.5 ng/ml) in studies A and B. The highest blood concentration measured throughout the three studies was 2.6 ng/ml. The cream was well tolerated, locally and systemically. The most common adverse event suspected to be related to study medication was a transient mild to moderate stinging sensation at the application site in 5/26 patients. There was no indication of any systemic adverse effect. The patients responded well to therapy with a rapid onset of action, usually within four days. Median reductions of EASI from baseline at day 22 were 55% (study A), 63% (study B), and 83% (study C).

Conclusion: Three weeks treatment of children and infants with extensive atopic dermatitis, using pimecrolimus cream 1% twice daily, is well tolerated and results in minimal systemic exposure, at which no systemic effect is expected.

Full Text

The Full Text of this article is available as a PDF (274K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R, Asher I, Beasley R, Björkstén B, Burr M, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125–138. [PubMed]
  • Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs. 2000 Jan;9(1):69–77. [PubMed]
  • Wellington K, Spencer CM. Sdz asm 981. BioDrugs. 2000 Dec;14(6):409–416. [PubMed]
  • Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999 Aug;141(2):264–273. [PubMed]
  • Meingassner JG, Grassberger M, Fahrngruber H, Moore HD, Schuurman H, Stütz A. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol. 1997 Oct;137(4):568–576. [PubMed]
  • Van Leent EJ, Gräber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998 Jul;134(7):805–809. [PubMed]
  • Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001 Apr;144(4):788–794. [PubMed]
  • Hebert AA, Warken KA, Cherill R. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg. 2001 Dec;20(4):260–267. [PubMed]
  • Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, Ortonne JP. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000 Jun;42(6):349–350. [PubMed]
  • Thaçi Diamant, Steinmeyer Katrin, Ebelin Marie-Eve, Scott Graham, Kaufmann Roland. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003;207(1):37–42. [PubMed]
  • Rappersberger Klemens, Komar Michael, Ebelin Marie-Eve, Scott Graham, Burtin Pascale, Greig Gerard, Kehren Jeanne, Chibout Salah-Dine, Cordier Andre, Holter Wolfgang, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 2002 Oct;119(4):876–887. [PubMed]
  • Van Leent Edwin J M, Ebelin Marie Eve, Burtin Pascale, Dorobek Birgit, Spuls Phyllis I, Bos Jan D. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology. 2002;204(1):63–68. [PubMed]
  • Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol. 2001 Mar;144(3):507–513. [PubMed]
  • Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno M, Burtin P. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol. 2001 Apr;144(4):781–787. [PubMed]
  • Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13–14. [PubMed]
  • Sampson HA. Pathogenesis of eczema. Clin Exp Allergy. 1990 Sep;20(5):459–467. [PubMed]
  • Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001 Feb;10(1):11–18. [PubMed]
  • Eichenfield Lawrence F, Lucky Anne W, Boguniewicz Mark, Langley Richard G B, Cherill Robert, Marshall Katharine, Bush Christopher, Graeber Michael. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002 Apr;46(4):495–504. [PubMed]
  • Kapp Alexander, Papp Kim, Bingham Ann, Fölster-Holst Regina, Ortonne Jean-Paul, Potter Paul C, Gulliver Wayne, Paul Carle, Molloy Stephen, Barbier Nathalie, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol. 2002 Aug;110(2):277–284. [PubMed]
  • Ho Vincent C, Gupta Aditya, Kaufmann Roland, Todd Gail, Vanaclocha Francisco, Takaoka Roberto, Fölster-Holst Regina, Potter Paul, Marshall Katherine, Thurston Mark, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr. 2003 Feb;142(2):155–162. [PubMed]

Figures and Tables

Figure 1
Pimecrolimus blood concentrations in children and infants on day 4 and day 22 of a three week treatment course.
Figure 2
Blood concentrations of pimecrolimus versus body surface area at baseline (day 1).
Figure 3
Median reduction (%) of EASI from baseline (day 1) during three weeks of treatment of paediatric atopic dermatitis patients with pimecrolimus 1% cream.

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...